John Allan, MD

Articles by John Allan, MD

Panelists discuss how step-up dosing protocols reduce cytokine release syndrome (CRS) risk in patients with high-risk disease and when modifications might be necessary as well as the incorporation of infection prevention strategies, including prophylactic antimicrobials, into management plans.

Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.

Latest Updated Articles



    Brand Logo

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    © 2025 MJH Life Sciences®

    All rights reserved.

    Secondary Brand Logo